Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · Real-Time Price · USD
62.22
-0.41 (-0.65%)
At close: Feb 27, 2026, 4:00 PM EST
62.00
-0.22 (-0.35%)
After-hours: Feb 27, 2026, 7:28 PM EST
Cytokinetics Revenue
In the year 2025, Cytokinetics had annual revenue of $88.04M with 376.56% growth. Cytokinetics had revenue of $17.76M in the quarter ending December 31, 2025, with 4.89% growth.
Revenue (ttm)
$88.04M
Revenue Growth
+376.56%
P/S Ratio
87.04
Revenue / Employee
$176,785
Employees
498
Market Cap
7.66B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 88.04M | 69.57M | 376.56% |
| Dec 31, 2024 | 18.47M | 10.94M | 145.34% |
| Dec 31, 2023 | 7.53M | -87.06M | -92.04% |
| Dec 31, 2022 | 94.59M | 24.16M | 34.30% |
| Dec 31, 2021 | 70.43M | 14.60M | 26.15% |
| Dec 31, 2020 | 55.83M | 28.96M | 107.79% |
| Dec 31, 2019 | 26.87M | -4.63M | -14.71% |
| Dec 31, 2018 | 31.50M | 18.13M | 135.64% |
| Dec 31, 2017 | 13.37M | -93.04M | -87.44% |
| Dec 31, 2016 | 106.41M | 77.75M | 271.30% |
| Dec 31, 2015 | 28.66M | -18.28M | -38.95% |
| Dec 31, 2014 | 46.94M | 16.29M | 53.16% |
| Dec 31, 2013 | 30.65M | 23.09M | 305.45% |
| Dec 31, 2012 | 7.56M | 3.56M | 88.98% |
| Dec 31, 2011 | 4.00M | 1.42M | 55.22% |
| Dec 31, 2010 | 2.58M | -78.96M | -96.84% |
| Dec 31, 2009 | 81.54M | 69.12M | 556.51% |
| Dec 31, 2008 | 12.42M | -1.20M | -8.82% |
| Dec 31, 2007 | 13.62M | 10.50M | 335.63% |
| Dec 31, 2006 | 3.13M | -5.79M | -64.91% |
| Dec 31, 2005 | 8.91M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Halozyme Therapeutics | 1.40B |
| Bio-Techne | 1.22B |
| Arrowhead Pharmaceuticals | 1.09B |
| Axsome Therapeutics | 638.50M |
| Krystal Biotech | 389.13M |
| Kymera Therapeutics | 39.21M |
| Arcellx | 22.29M |
CYTK News
- 4 days ago - Cytokinetics, Incorporated (CYTK) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 4 days ago - Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 11 days ago - Cytokinetics Announces European Commission Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy - GlobeNewsWire
- 16 days ago - Cytokinetics to Announce Fourth Quarter Results on February 24, 2026 - GlobeNewsWire
- 19 days ago - Cytokinetics Announces Recipients of Its Eighth Annual Communications Grant Program - GlobeNewsWire
- 4 weeks ago - Cytokinetics Announces MYQORZO™ (aficamten) Now Available in the U.S. for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms - GlobeNewsWire
- 5 weeks ago - The Law Offices of Frank R. Cruz Announces Investigation of Cytokinetics, Incorporated (CYTK) on Behalf of Investors - Business Wire
- 5 weeks ago - Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire